Wolverine Legal Status, FDA 503A Category, and Compounding Access

Where Wolverine Legal Status Stands — and Where It Is Heading

The Wolverine legal status question has real forward momentum: access to its component peptides is under active FDA review and may expand in 2026. Anchoring that momentum is a concrete, scheduled fact — the FDA's Pharmacy Compounding Advisory Committee (PCAC) is set to meet on July 23-24, 2026 to discuss these peptides as candidates for the Section 503A Bulks List ^[13]. That is the honest leading edge of this story, and it is a scheduled discussion, not a decision.

The present-tense fact has to be stated plainly alongside it. Both of Wolverine's components are currently classified by the FDA as 503A "Category 2" bulk drug substances — substances FDA identified as ones that may present significant safety risks — effective with the FDA's September 29, 2023 update to the list of nominated substances ^[12]. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, which means compounding-pharmacy access to these peptides is currently restricted. Neither peptide is an FDA-approved drug, and the blend has no approved indication ^[12].

So both things are true at once. The current category is restrictive; the trajectory is open. The blend's WADA prohibition status is covered below, and none of what follows is medical or legal advice — it is general information about the regulatory landscape.

What 503A Category 2 Means for Both Components

Under the Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight ^[12]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet listed are evaluated by FDA through a public nomination process with input from PCAC ^[12].

Within that framework, FDA's interim policy sorted nominated substances into Category 1 (covered by enforcement discretion while under evaluation) and Category 2 (identified as raising significant safety risks, and not covered by that discretion) ^[12]. Both of Wolverine's components sit in Category 2 today, with no component carve-out:

• BPC-157 (evaluated as "BPC-157 (free base)" and "BPC-157 acetate") is in Category 2 for 503A compounding, effective with the September 29, 2023 list update, with FDA citing concerns including potential immunogenicity for certain routes and complexities with peptide-related impurities and active-ingredient characterization ^[12].
• TB-500 — listed by FDA as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — is in Category 2 for 503A compounding, effective with the same September 29, 2023 update, with FDA citing concerns including potential immunogenicity for certain routes and a lack of important safety information ^[12].

FDA's own list entry establishes the relationship between the marketed name and the fragment: TB-500 is the LKKTETQ fragment associated with Thymosin Beta-4 ^[12].

The July 2026 Advisory-Committee Review

Both components are on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[13]. There is no carve-out: BPC-157 and TB-500 are both currently Category 2 and both are under this one scheduled review.

What that meeting is, precisely: a scheduled, advisory discussion of substances under evaluation. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC — being discussed by the committee is a step in evaluation, not a final listing decision ^[12]. The outcome of the July 23-24, 2026 meeting is not known, and nothing on this page should be read as asserting a reclassification, a listing, or a removal as already done, dated, or certain. The momentum is genuine and the date is real; the result is still ahead.

How Legally Compounded Peptide Access Works

In the U.S., a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription ^[12]. The preparation is then made either by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility ^[12]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription issued — it is a route to a licensed-prescriber consultation, not a separate legal status, and it does not change which substances are eligible to be compounded ^[12].

The eligibility caveat is the part that currently binds for these peptides. A compounder may use a requested active ingredient only if that ingredient is permitted under the 503A/503B bulk-substance rules; ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[12]. As long as BPC-157 and TB-500 remain in Category 2, that is the operative constraint. This is general information about how the pathway works, not a route to obtain a restricted substance and not medical or legal advice.

Are BPC-157 and TB-500 FDA Approved or Banned by WADA?

Neither is FDA-approved for human use, and the blend has no approved indication. In 2023 FDA placed both in 503A Category 2 — bulk substances identified as possibly presenting significant safety risks — so neither is within FDA's enforcement-discretion policy for compounding ^[12]. Both constituents are also prohibited by the World Anti-Doping Agency: BPC-157 under the S0 non-approved-substances category, and TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories.

Is Wolverine Legal?

Neither constituent is an FDA-approved drug and the blend has no approved therapeutic indication; both are sold by research suppliers for laboratory use only ^[12]. Both components are currently 503A Category 2, so they are not within FDA's enforcement-discretion policy for compounding, and both are WADA-prohibited in and out of competition for the relevant classes.

Can You Get BPC-157 From a Compounding Pharmacy?

Currently, access is restricted. FDA placed BPC-157 in 503A Category 2 — bulk substances not within its enforcement-discretion policy — effective with the September 29, 2023 list update, so it is not eligible for routine 503A compounding while that status stands ^[12]. BPC-157 is on the July 23-24, 2026 PCAC agenda as a 503A bulks-list candidate, which is a scheduled evaluation, not a change in current status ^[13].

What Is the FDA 503A Status of Wolverine?

Both components are FDA 503A Category 2 bulk substances today, effective with the September 29, 2023 update, and neither is FDA-approved, so the blend has no current 503A compounding pathway ^[12]. Both BPC-157 and TB-500 are on the July 23-24, 2026 PCAC agenda as substances being considered for the 503A Bulks List — a scheduled review, not a decision ^[13].